S&P 500   3,841.47
DOW   30,996.98
QQQ   325.42
pixel
S&P 500   3,841.47
DOW   30,996.98
QQQ   325.42
pixel
S&P 500   3,841.47
DOW   30,996.98
QQQ   325.42
pixel
S&P 500   3,841.47
DOW   30,996.98
QQQ   325.42
pixel
Log in
ASX:HSO

Healthscope Stock Forecast, Price & News

Add
Compare
Today's Range N/A
50-Day Range N/A
52-Week Range N/A
Volume38.30 million shs
Average VolumeN/A
Market CapitalizationN/A
P/E RatioN/A
Dividend Yield2.86%
BetaN/A
Healthscope Limited provides healthcare services in Australia and New Zealand. The company operates through Hospitals Australia and Pathology New Zealand segments. It operates 43 private hospitals, including 30 acute hospitals, 7 mental health hospitals, and 6 rehabilitation hospitals with approximately 5,000 inpatient beds. The company also provides human pathology services under the Labtests, Southern Community Laboratories, and Northland Pathology brands; and veterinary and analytical pathology services under the Gribbles brand. The company was formerly known as Healthscope Hospitals Holdings Pty. Ltd. and changed its name to Healthscope Limited in July 2014. Healthscope Limited was founded in 1985 and is headquartered in Melbourne, Australia.

MarketRank

Overall MarketRank

0.79 out of 5 stars

Analyst Opinion: 0.0Community Rank: 3.1Dividend Strength: 0.8Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -

Industry, Sector and Symbol

Industry Hospitals
Sub-IndustryN/A
SectorMedical
CUSIPN/A
CIKN/A
Phone+61-3-99267500
EmployeesN/A

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A

Profitability

Miscellaneous

Next Earnings DateN/A
OptionableNot Optionable

Receive HSO News and Ratings via Email

Sign-up to receive the latest news and ratings for HSO and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Healthscope (ASX:HSO) Frequently Asked Questions

What stocks does MarketBeat like better than Healthscope?

Wall Street analysts have given Healthscope a "N/A" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Healthscope wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

How were Healthscope's earnings last quarter?

Healthscope Ltd (ASX:HSO) announced its quarterly earnings results on Thursday, February, 14th. The company reported $0.04 EPS for the quarter.
View Healthscope's earnings history
.

Is Healthscope a good dividend stock?

Healthscope pays an annual dividend of A$0.07 per share and currently has a dividend yield of 2.86%.
View Healthscope's dividend history.

Who are some of Healthscope's key competitors?

What other stocks do shareholders of Healthscope own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Healthscope investors own include UBS ETRACS CMCI Energy Total Return ETN (UBN), Primary Health Care Limited (PRY.AX) (PRY) and Fortescue Metals Group Limited (FMG.AX) (FMG).

Who are Healthscope's key executives?

Healthscope's management team includes the following people:
  • Mr. Gordon Scott Ballantyne, MD, CEO & Director (Age 54)
  • Mr. Michael Sammells, Chief Financial Officer
  • Mr. Mark Briscoe, Gen. Mang. of Operations
  • Mr. David Shirer, Gen. Mang. of Investor Relations
  • Ms. Ingrid A. Player, Group Exec. of Legal, Governance & Sustainability, Gen. Counsel and Sec. (Age 46)

What is Healthscope's stock symbol?

Healthscope trades on the ASX under the ticker symbol "HSO."

How big of a company is Healthscope?

Healthscope has a market capitalization of $0.00. Healthscope employs 17,100 workers across the globe.

What is Healthscope's official website?

The official website for Healthscope is www.healthscope.com.au.

How can I contact Healthscope?

Healthscope's mailing address is Level 1, 312 St. Kilda Road, MELBOURNE, VIC 3001, Australia. The company can be reached via phone at +61-3-99267500.

This page was last updated on 1/23/2021 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.